Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Ripretinib

Qinlock

Stage Approved

Sponsor Deciphera Pharmaceuticals

Route oral tablet

Modality small molecule

Class switch-control KIT/PDGFRA TKI

Mechanism switch-control tyrosine kinase inhibitor

Target KIT (TEC-0117)

Target PDGFRA

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f18e462-03dd-4296-a02a-a0577e3ee78d

Median PFS (months) (95% CI) 6.3 (4.6, 6.9) 1.0 (0.9, 1.7) Hazard ratio 0.15 ... Overall Response Rate (%) 9 0 ... Median OS (months) 15.1 (12.3, 15.1) 6.6 (4.1, 11.6) Hazard ratio 0.36

Qinlock USPI section 1 and section 14, Table 6, INVICTUS (NCT03353753)

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/35947817/

median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72) ... Median PFS for ripretinib and sunitinib (KIT exon 11 ITT) was 8.3 and 7.0 months ... Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03) ... grade 3/4 treatment-emergent adverse events (41.3% v 65.6%

Bauer S et al. J Clin Oncol 2022;40:3918-3928, PMID 35947817, abstract

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.TPS848

pts harboring primary KIT exon 11 mutations with secondary resistance mutations exclusively in KIT exons 17/18 derived PFS benefit with ripretinib vs sunitinib (median, 14.2 vs 1.5 months; HR, 0.22; 95% CI, 0.11 to 0.44; nominal P <0.0001; Heinrich MC et al. Nat Med. 2024) ... A total of 54 pts will be randomized (2:1)

J Clin Oncol 43(4_suppl) TPS848 (2025), INSIGHT design and INTRIGUE exploratory ctDNA citation

publication, as of 2026-11-07

https://link.springer.com/article/10.1245/s10434-024-16853-x

patients with primary KIT exon 11 and secondary exon 13/14 mutations detected in ctDNA had significantly improved outcomes when treated with sunitinib (median PFS 15.0 vs. 4.0 months; nominal p = 0.0005)

Annals of Surgical Oncology, INSIGHT trial article (2025)

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03353753

A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03673501

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05734105

An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

INVICTUS

Registry NCT03353753

Phase Phase 3

Status Completed

Enrollment 129

Start 2018-02-27

Primary completion 2019-05-31

Study completion 2022-05-11

Ripretinib 150 mg

Dose 150 mg

Regimen once daily

Comparator placebo

Population GIST after imatinib, sunitinib and regorafenib

Estimand ITT

median progression-free survival (BICR): 6.3 months, primary analysis

progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis

objective response rate (BICR): 9%, primary analysis

median overall survival: 15.1 months, not tested for significance

Placebo

Dose placebo

Regimen once daily

Population GIST after imatinib, sunitinib and regorafenib

Estimand ITT

median progression-free survival (BICR): 1 months, primary analysis

median overall survival: 6.6 months, 66% switched to ripretinib

INTRIGUE

Registry NCT03673501

Phase Phase 3

Status Active, not recruiting

Enrollment 453

Start 2019-02-08

Primary completion 2021-09-01

Study completion 2027-12

Catalyst Primary completion. 09.01.2021. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Ripretinib 150 mg

Dose 150 mg

Regimen once daily

Comparator sunitinib 50 mg 4/2

Population GIST after imatinib (ITT n = 226)

Estimand ITT

median progression-free survival (IRR), ITT: 8 months, primary analysis

progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant

median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis

objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03

grade 3 or 4 treatment-emergent adverse events: 41.3%, primary analysis

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P

Sunitinib 50 mg 4/2

Dose 50 mg

Regimen once daily, 4 weeks on 2 off

Population GIST after imatinib (ITT n = 227)

Estimand ITT

median progression-free survival (IRR), ITT: 8.3 months, primary analysis

median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis

objective response rate, KIT exon 11 ITT: 14.6%, primary analysis

grade 3 or 4 treatment-emergent adverse events: 65.6%, primary analysis

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory

median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory

INSIGHT

Registry NCT05734105

Phase Phase 3

Status Active, not recruiting

Enrollment 54

Start 2023-12-13

Primary completion 2027-12

Study completion 2028-12

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Ripretinib 150 mg

Dose 150 mg

Regimen once daily

Comparator sunitinib 50 mg 4/2

Population 2L GIST, ctDNA KIT exon 11 + 17/18, no exon 9/13/14

Estimand ITT

Sunitinib 50 mg 4/2

Dose 50 mg

Regimen 4 weeks on 2 off

Population 2L GIST, ctDNA KIT exon 11 + 17/18

Estimand ITT